Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsChronic neutrophilic leukemia: a clinical perspectiveJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsG-CSF and GM-CSF in NeutropeniaChronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and managementCIViC databaseEvaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literatureClonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesRuxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsSignificant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.Activity of single-agent decitabine in atypical chronic myeloid leukemia.Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaCSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemiaMolecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.Therapeutically Targetable ALK Mutations in LeukemiaTargeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.Diagnosis, complications and management of chronic neutrophilic leukaemia: A case reportChronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report.Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia developmentIdentification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisIdentification of AIM2 as a downstream target of JAK2V617F.The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case.Short telomere length and its correlation with gene mutations in myelodysplastic syndrome.The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatmentBRCC3 mutations in myeloid neoplasms.The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
P2860
Q26738514-8FBAF96F-3B84-4CB1-AB33-905A3F2C7904Q26778929-1310679D-D8C3-45F0-B493-50A434610E64Q26781167-E6C79B1C-CB04-41BD-BF39-DE66224EF7F7Q26782539-256B0CA3-34D3-4DB2-897D-51AB00E887B8Q26800954-6E58443F-E72F-4FDF-ABF1-A4E0EF5C3DFDQ27009366-BB9A2CF7-2F92-467C-A683-3E0087D55D93Q27612411-A0F61273-5E02-4A31-BE40-1E482F57DB5CQ28083489-B978E674-4767-4086-9CD6-1C3EE0887B4DQ28392451-C4380963-D7AD-4603-BE45-FF4ABCA29999Q33417217-5FBABDC7-F129-47E0-8B92-A76C2EBA52CCQ33417454-825B153A-CFB6-4975-905A-2D11BFC09647Q33421772-7FA852D8-0C2E-45F0-A49D-8E206E28F5A5Q33425922-17B75FB5-85A4-4F22-ABFA-A554965D7431Q33591367-A1A26354-B63D-481D-A561-5558EF23245DQ33697252-280B7D58-2450-4169-B92D-B089CDEB04EEQ33794297-B4B564FA-EEA8-4A42-988A-C74A9CB8B9E9Q33796552-5A644F79-232B-45F6-A1E2-F9FD4149A27FQ33909621-81DBE37C-2C1D-4B6D-BC2E-2A7ED0443B80Q34355272-EC47FDDB-0279-4AE9-803F-2B8CEDBECCAEQ34700714-B3B3A7FF-D02E-402C-9002-B05BEE902265Q35132241-3D759446-6303-41F3-B72E-D200914C801CQ35542942-90A17BE6-02DD-46CD-BB66-5022DA735941Q35610140-7787D2A6-A96F-4806-AFAA-FBE1562905A7Q35676273-26FB68CB-FDAE-41C8-A0A1-690A4F3867B2Q35727453-BEA9D4D4-2EB2-4D0A-BF52-A81024EB8792Q35758855-D63A08CE-B705-4C5F-BCCF-319BCDD6D2C4Q35944494-D47E345A-FD53-4578-A9FB-A7BBC3097291Q36291255-27A616A2-E8E0-4845-BE8E-BB2F66DD11E1Q36437137-026D6DD7-4A67-43EB-B03E-DB82C92FD8CFQ36437173-C565E909-6BA0-41A2-923A-BC8EDD98BB77Q36513561-DE55D3E9-8387-4E7E-A027-D899EC45B693Q36535279-A99D4A90-D469-48A1-BFDB-8BBABC88880EQ36693223-712C5A14-1611-4C13-B41A-812262099786Q36708989-199B56A1-023E-4E38-9651-FA034E390246Q36851425-F71D5DF7-45B1-45C9-A234-A077C4E53830Q37133403-238A9823-8988-4D77-A784-21B8F700217DQ37151676-F4F2876A-722B-49D6-B7B7-85B284889CD3Q37216363-88C69A9B-171A-4542-8BDB-E5545985A5AEQ37334721-5D846CF0-D8C4-40D4-AF15-AAFEDBC06774Q37349392-40471046-2285-4267-8E0C-E54CEB2854F3
P2860
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@ast
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@en
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
@nl
type
label
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@ast
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@en
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
@nl
altLabel
OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML
@en
prefLabel
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@ast
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@en
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
@nl
P2093
P2860
P50
P3181
P356
P1476
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
@en
P2093
Anupriya Agarwal
Basem Goueli
Beth Wilmot
Christopher A Eide
Cristina E Tognon
Daniel A Pollyea
Daniel Bottomly
J Blake Pond
Jason Gotlib
Julia E Maxson
P2860
P304
P3181
P356
10.1056/NEJMOA1214514
P407
P577
2013-05-09T00:00:00Z